Zacks Investment Research lowered shares of ELEKTA (NASDAQ:EKTAY) from a buy rating to a hold rating in a research note released on Friday morning.
According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden. “
Shares of ELEKTA (EKTAY) traded up 0.52% during mid-day trading on Friday, hitting $9.63. 908 shares of the stock were exchanged. The firm has a market cap of $3.68 billion and a price-to-earnings ratio of 155.32. The stock has a 50-day moving average price of $10.23 and a 200 day moving average price of $9.86. ELEKTA has a 52-week low of $7.97 and a 52-week high of $11.18.
ILLEGAL ACTIVITY NOTICE: “ELEKTA (EKTAY) Lowered to Hold at Zacks Investment Research” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/28/elekta-ektay-lowered-to-hold-at-zacks-investment-research.html.
ELEKTA Company Profile
Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies.
Receive News & Ratings for ELEKTA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA and related companies with MarketBeat.com's FREE daily email newsletter.